including ALPROLIX®, ELOCTATE®, QFITLIA™, JIVI® and ALTUVIIIO®. Dr. Mei is co-inventor of the latter two globally approved drugs, and has led clinical development for multiple new molecular ...

The approval allows Imfinzi to be used in... Sanofi’s New Hemophilia Drug Qfitlia Gains FDA Approval with Breakthrough Bimonthly Dosing The U.S. Food and Drug Administration (FDA) has approved ...

The US Food and Drug Administration granted clearances for testing instruments, a blood clot drug companion diagnostic test, and infectious disease tests, among other devices.

including ALPROLIX®, ELOCTATE®, QFITLIA™, JIVI® and ALTUVIIIO®. Dr. Mei is co-inventor of the latter two globally approved drugs, and has led clinical development for multiple new molecular entities ...

The approval allows Imfinzi to be used in... Sanofi’s New Hemophilia Drug Qfitlia Gains FDA Approval with Breakthrough Bimonthly Dosing The U.S. Food and Drug Administration (FDA) has approved ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ...

BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May ...

Sanofi (NASDAQ:SNY) announced Tuesday that its TIDE-Asthma Phase 2 study for its T-cell-depleting monoclonal antibody amlitelimab didn’t reach the primary endpoint for the highest dose level but ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...